Financial reports
10-K
2023 FY
Annual report
26 Mar 24
10-Q
2023 Q3
Quarterly report
1 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
31 Oct 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
28 Mar 22
Current reports
8-K
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
1 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
21 Dec 23
8-K
GT Biopharma Announces IND Submission
4 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
5 Jul 23
8-K
GT Biopharma Names Charles J. Casamento to the Board of Directors
4 May 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
28 Feb 23
8-K
GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering
4 Jan 23
8-K
Departure of Directors or Certain Officers
13 Dec 22
8-K
Amendments to Articles of Incorporation or Bylaws
9 Nov 22
Registration and prospectus
424B5
Prospectus supplement for primary offering
3 Jan 23
S-3
Shelf registration
13 Oct 22
S-8
Registration of securities for employees
25 Jul 22
S-1
IPO registration
22 Apr 21
POS AM
Prospectus update (post-effective amendment)
22 Apr 21
424B4
Prospectus supplement with pricing info
12 Feb 21
S-1MEF
Registration of additional securities for an S-1
10 Feb 21
S-1/A
IPO registration (amended)
9 Feb 21
8-A12B
Registration of securities on exchange
8 Feb 21
S-1/A
IPO registration (amended)
8 Feb 21
Proxies
DEFA14A
Additional proxy soliciting materials
6 Nov 23
DEFA14A
Additional proxy soliciting materials
6 Nov 23
DEF 14A
Definitive proxy
6 Nov 23
PRE 14A
Preliminary proxy
27 Oct 23
DEFA14A
Additional proxy soliciting materials
5 May 23
DEFR14A
Revised proxy
5 May 23
DEF 14A
Definitive proxy
1 May 23
DEFA14A
Additional proxy soliciting materials
4 Oct 22
DEF 14A
Definitive proxy
17 Aug 22
DEF 14A
Definitive proxy
29 Apr 22
Other
EFFECT
Notice of effectiveness
21 Oct 22
UPLOAD
Letter from SEC
19 Oct 22
CORRESP
Correspondence with SEC
18 Oct 22
UPLOAD
Letter from SEC
26 Jan 22
CORRESP
Correspondence with SEC
29 Dec 21
UPLOAD
Letter from SEC
15 Dec 21
EFFECT
Notice of effectiveness
28 Apr 21
EFFECT
Notice of effectiveness
23 Apr 21
CORRESP
Correspondence with SEC
23 Apr 21
UPLOAD
Letter from SEC
23 Apr 21
Ownership
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G
CYTOVANCE BIOLOGICS INC
19 Sep 23
4
Michael Martin Breen
15 Aug 23
4
Manu Ohri
15 Aug 23
4
CHARLES J CASAMENTO
21 Jun 23
3
CHARLES J CASAMENTO
4 May 23
4
Michael Martin Breen
11 Apr 23
4
Manu Ohri
10 Apr 23
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 23
4
Michael Martin Breen
1 Feb 23